Finance
AstraZeneca CEO says Europe must invest more to protect its 'health sovereignty'
Published by Global Banking & Finance Review®
Posted on April 23, 2025
2 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 23, 2025
2 min readLast updated: January 24, 2026
AstraZeneca's CEO urges Europe to invest more in health sovereignty, citing the need for innovation and competitiveness in the global market.
By Maggie Fick
LONDON (Reuters) -AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending it now must do the same and invest more to protect its health sovereignty amid a shifting world order.
Soriot was responding to a Reuters request for comment on a letter by the CEOs of European drugmakers Novartis and Sanofi published on Wednesday in the Financial Times in which they said European price controls on medicines hurt innovation and made the region less attractive, "penalising" innovation.
"Europe spends a substantially lower share of GDP on innovative medicines than the U.S. and, as a result, is falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk," Soriot said in a statement.
Despite its heavy spending on medicines and healthcare overall, the United States has the worst health outcomes among countries in the Organisation for Economic Cooperation and Development. However, European pharma bosses' comments show their concern that U.S. President Donald Trump's efforts to bring more investment to his country are reducing incentives to invest in Europe.
In January, AstraZeneca, scrapped plans to invest 450 million pounds ($598.46 million) in its vaccine manufacturing plant in England, citing a cut in British government support and has not announced new investments since.
Last November, the Anglo-Swedish drugmaker unveiled a $3.5 billion investment to expand its manufacturing footprint in the U.S. and do more research and development there.
($1 = 0.7519 pounds)
(Reporting by Maggie FickEditing by Jane Merriman and Tomasz Janowski)
The main topic is AstraZeneca CEO's call for Europe to increase investment in health sovereignty to boost innovation and competitiveness.
Health sovereignty is crucial for ensuring a region's ability to innovate and protect the health of its population amidst global competition.
AstraZeneca canceled a UK investment due to reduced support and is expanding its R&D and manufacturing in the U.S.
Explore more articles in the Finance category
